showed that oral supplementation with AKK in nonresponders restored the efficacy of PD-1 blockade in an IL-12-dependent manner by increasing the recruitment of CCR9+, CXCR3+, and CD4+ T lymphocytes to tumor beds in mice (27). The gene discussed is PDCD1; the disease is neoplasm.